| |
Events/person-years
|
Age-adjusted HR (95% CI)
|
MV-adjusted HRa (95% CI)a
|
|---|
|
Age at diagnosis
|
|
Cancer-free
|
67/3509
|
1.00 (reference)
|
1.00 (reference)
|
|
≤ 50 years
|
27/651
|
2.34 (1.46–3.75)
|
1.98 (1.21–3.24)
|
|
> 50 years
|
18/375
|
1.64 (0.93–2.88)
|
1.34 (0.75–2.40)
|
|
Menopausal status at diagnosis
|
|
Cancer-free
|
67/3509
|
1.00 (reference)
|
1.00 (reference)
|
|
Premenopausal at diagnosis
|
27/728
|
1.97 (1.24–3.12)
|
1.76 (1.09–2.84)
|
|
Postmenopausal at diagnosis
|
18/298
|
2.05 (1.15–3.64)
|
1.58 (0.86–2.89)
|
|
ER statusb
|
|
Cancer-free
|
67/3509
|
1.00 (reference)
|
1.00 (reference)
|
|
ER-negative
|
7/200
|
1.68 (0.76–3.72)
|
1.26 (0.54–2.94)
|
|
ER-positive
|
32/611
|
2.32 (1.52–3.55)
|
2.10 (1.34–3.29)
|
- Abbreviations: ER Estrogen receptor, MV Multivariable
- aAdjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at age < 45 years (yes, no), body mass index (kg/m2), physical activity (MET-h/wk), smoking status (never, ever), alcohol intake (g/d), and hormone replacement therapy (never, ever)
- bBreast cancer survivors were restricted to stages I–III
